Evidence map›Paper›PMID 41306029›Full record

ArticleThe Journal of dermatology2026

Health-Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan.

Naoki Oiso, Yasutaka Mizoro, Kazumasa Kamei, Kenichi Yamanaka, Masato Hoshi, Kouki Nakamura

Abstract read
In one paragraph

Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naoki OisoDepartment of Dermatology, Kindai University Nara Hospital, Nara, Japan.ORCID https://orcid.org/0000-0001-5593-6496
Yasutaka MizoroSpecialty Care Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0002-5081-4884
Kazumasa KameiJapan Access and Value, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0001-7220-5142
Kenichi YamanakaSpecialty Care Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0009-0001-0649-7148
Masato HoshiSpecialty Care Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0003-2874-1807
Kouki NakamuraSpecialty Care Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0002-2296-6004

Funding

Pfizer Japan Inc.
6 · The paper itself

Abstract

Vitiligo is a disorder characterized by depigmentation of the skin and is known to impact patients' health-related quality of life (HRQoL). In Japan, HRQoL studies on vitiligo remain limited in size and scope, and factors contributing to impaired HRQoL, as well as the psychological burden, have not been adequately evaluated. This study aimed to assess HRQoL and symptoms of anxiety and depression in patients with vitiligo in Japan. A web-based survey was completed by 271 patients with vitiligo aged 18 to 79 years. The survey included the 12-item Short Form Health Survey version 2 (SF-12v2) and the Dermatology Life Quality Index (DLQI) to assess HRQoL, as well as the Hospital Anxiety and Depression Scale (HADS). The role/social component summary score (mean ± standard deviation) of the SF-12v2 in vitiligo patients was 45.8 ± 14.5, which was lower than the Japanese population norm (national standard values for Japanese). Based on the DLQI, which is specific to dermatologic diseases, 62.7% of patients reported at least a small effect on their daily lives. HADS anxiety and depression scores showed that 38.0% and 40.3% of patients, respectively, were classified as doubtful or definite cases. Subgroup analyses revealed that higher DLQI and HADS scores were associated with sex, age, disease duration, affected body surface area (BSA), and history of relapse. Notably, nonlinear associations in these measures were observed for disease duration and affected BSA, with the highest scores seen in patients with an intermediate range of disease duration and affected BSA. These findings underscore the need for timely and sustained treatment strategies to control symptoms, reduce psychological distress, and prevent relapse, which may help not only improve clinical outcomes but also maintain long-term HRQoL in individuals with vitiligo.

Indexed as

AnxietyDepressionQuality of LifeVitiligoAdolescentAdultAgedCost of IllnessFemaleHealth SurveysHumansJapanMaleMiddle AgedSurveys and QuestionnairesYoung Adultobservational studypatient reported outcome measurespsychosocial functioningquality of lifevitiligo

Identifiers

PMID41306029
PMCPMC12877968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.